tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
AIM ImmunoTech reports Q3 EPS ($1.57) vs ($6.00) last year
PremiumThe FlyAIM ImmunoTech reports Q3 EPS ($1.57) vs ($6.00) last year
2M ago
AIM ImmunoTech Reports Q3 2025 Financial Results
Premium
Company Announcements
AIM ImmunoTech Reports Q3 2025 Financial Results
2M ago
AIM ImmunoTech Delays Q3 2025 Report Filing
Premium
Company Announcements
AIM ImmunoTech Delays Q3 2025 Report Filing
2M ago
AIM ImmunoTech Presents at Maxim Growth Summit 2025
PremiumCompany AnnouncementsAIM ImmunoTech Presents at Maxim Growth Summit 2025
3M ago
AIM ImmunoTech presents Phase 1a trial data for faridoxorubicin
Premium
The Fly
AIM ImmunoTech presents Phase 1a trial data for faridoxorubicin
3M ago
AIM ImmunoTech secures patent in Japan through 2039 for therapy using Ampligen
Premium
The Fly
AIM ImmunoTech secures patent in Japan through 2039 for therapy using Ampligen
4M ago
AIM ImmunoTech announces four presentations on Ampligen at MSCI MSCS-2025
PremiumThe FlyAIM ImmunoTech announces four presentations on Ampligen at MSCI MSCS-2025
5M ago
AIM ImmunoTech highlights recent key financial milestones
Premium
The Fly
AIM ImmunoTech highlights recent key financial milestones
5M ago
AIM ImmunoTech Closes $8 Million Public Offering
Premium
Company Announcements
AIM ImmunoTech Closes $8 Million Public Offering
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100